Chuangsheng Group TST005 has been approved by the FDA for clinical use, and its many new drugs are under development, covering popular targets such as PD-L1 and Claudin 18.2

Recently, Chuangsheng Group can be described as good news again and again
.
Following the news of the upcoming IPO, on April 21, Chuangsheng Group announced that its new anti-PD-L1 and TGF-β bifunctional antibody ( TST005 ) has obtained the approval of the US FDA to carry out clinical trials

TST005 is a bifunctional antibody that simultaneously targets two pathways commonly used by cancer cells to escape immunosuppression, namely transforming growth factor-β (TGF-β) and programmed cell death ligand-1 (PD-L1)
.
TST005 is composed of a high-affinity PD-L1 antibody and an engineered TGF-β receptor type II protein fused to its C-terminus

In multiple homologous mouse tumor models, TST005 can significantly increase the infiltration of CD8-positive T cells into PD-L1-expressing tumors and shows a dose-dependent manner in homologous mouse tumor models with high TGF-β expression.
Tumor growth inhibition
.
TST005 is well tolerated in non-human primates and shows linear PK characteristics

TST005 is currently one of the few leading drug candidates for PD-L1/TGF-β dual-functional antibodies that is currently under clinical development in the world
.
In addition, Chuangsheng Group has 9 new drug molecules in its R&D pipeline, many of which involve popular targets such as PD-L1, Claudin 18.

MSB2311

MSB2311 is an investigative pH-dependent humanized antibody that targets PD-L1
.
MSB2311 can bind to PD-L1 on tumor cells and block the interaction between PD-L1 and PD1 (receptors on T effector cells)

TST001

TST001 is the second generation anti-Claudin 18.
2 antibody
.
Claudin 18.

With advanced technology, the fucose modification ratio of TST001 can be greatly reduced in production, which further enhances the tumor-killing activity of TST001
.
In various preclinical in vitro pharmacodynamic studies, TST001 showed stronger anti-tumor activity than similar molecules

TST002

TST002 is a humanized sclerostin monoclonal antibody drug candidate for osteoporosis
.
Studies have shown that blocking sclerostin activity is an effective way to increase bone mineral density (BMD) and reduce fractures in people receiving anti-sclerostin antibody treatment or naturally occurring gene deletions

TST004

TST004 is a humanized monoclonal antibody targeting mannan-binding lectin serine protease 2 (MASP2).
It is designed to prevent complement-mediated inflammation in the lectin pathway.
Chuangsheng Group plans to develop TST004 for IgA nephropathy
.
The current treatment of IgA nephropathy is still based on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), supplemented with corticosteroids and other immunosuppressive therapies, but the toxicity is too high, so long-term use of these Medications can bring additional risks to patients
.
The development of TST004 will bring good news to the majority of patients with IgA nephropathy
.

       In addition, Chuangsheng Group is still developing drug candidates:

       TST003: A potential first therapeutic antibody drug candidate targeting a novel immunomodulatory protein produced by tumor-associated fibroblasts or tumor cells with a mesenchymal phenotype in the world;

       TST006: A bispecific antibody that binds Claudin 18.
2 and PD-L1, which can be used to treat a variety of solid tumors, such as gastric cancer;

       TST008: A trifunctional antibody that binds to MASP2 antibody and fused with truncated transmembrane activator and CAML interacting molecule (TACI) protein, has the potential to treat autoimmune diseases, such as systemic lupus erythematosus (SLE)
.

       The following table summarizes drug candidates currently under development in multiple therapeutic areas in China and around the world:

       Chuangsheng Group R&D pipeline (source: company official website)

       Chuangsheng Group is an international biopharmaceutical company with fully integrated capabilities in biopharmaceutical R&D, clinical and production
.
The company has successfully established a global business layout and looks forward to making more breakthroughs in clinical production and future commercial production
.

       Reference source:

       1.
Retrieved Apr 21, 2021, from https://       2.
Prospectus of Chuangsheng Group;

       3.
Chuangsheng official website
.